Project description DEENESFRITPL Revolutionising the process of alternative meat production The growing demand for meat in combination with the attempt to reduce total CO2 emissions from livestock has led to the pursuit of biotechnical solutions for meat production. One of the main practices introduced to address this challenge is cell-cultured meat (CCM) production, achieved through the growth of meat cells from a small sample of stem cells collected from the animal. The EU-funded CCMeat project will introduce a set of innovative, affordable, endotoxin-free growth factors designed specifically for the CCM industry. Through its innovative technology, CCMeat aims to help CCM producers bring their alternative meat products to the market and contribute to reducing the negative consequences of conventional meat production. Show the project objective Hide the project objective Objective ORF Genetics is a female-lead plant biotechnology company biofarming protein in barley for use in medical research, stem cell technology and skincare. Since 2001, we have produced over 50 proteins, specializing in human growth factors (GFs) which regulate the growth and development of cells. Our main focus has been on GFs for skincare use and now with our team of over 80 qualified scientists, researchers, marketers and more, we are aiming at a larger market, the cell-cultured meat (CCM) industry. The CCMeat project removes the biggest hurdle CCM producers are facing to bring their alternative meat products to market. With innovations in our technology we will produce affordable, endotoxin-free growth factors designed specifically for CCM: the MESOkine™ line (patent to be filed in June 2020). This will be done by scaling cultivation from our 2000m2 state-of-the-art geothermally powered greenhouse in Iceland to in-field cultivation sites. We will also introduce a protein processing technology (patent to be filed in July 2020) that will substantially decrease production costs and lead to greater GF yields. By 2030, our MESOkine™ line will drop GF prices from 3000€/kg of cultured meat to approximately 0.7€/kg meat at scales necessary to produce over 7 million tonnes of meat. We are already providing samples to CCM customers and expect to reach a 40% market share within 5 years with our strong first mover advantage. MESOkine™ sales are expected to rise exponentially and reach profitability of €19 million by 2026. As the demand for meat continues to grow, this innovation will have a profound impact on our planet, enabling CCM to avert many of the negative consequences of conventional meat production. This includes reducing greenhouse gases by more than 250 million tonnes of CO2-eq emissions, deforestation by producing 7-52 times as much meat with one hectare of land, and antibiotic resistance by sparing over 1000 tonnes of livestock antibiotic use. Fields of science natural sciencesbiological sciencesbiochemistrybiomoleculesproteinsmedical and health sciencesmedical biotechnologycells technologiesstem cellsmedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsantibioticsagricultural sciencesanimal and dairy sciencedomestic animalsanimal husbandrymedical and health sciencesbasic medicinepharmacology and pharmacydrug resistanceantibiotic resistance Keywords Cell-cultured meat affordable synthetic meat growth factors biofarming barley Programme(s) H2020-EU.3. - PRIORITY 'Societal challenges Main Programme H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies Topic(s) H2020-EIC-SMEInst-2020-4 - H2020-EIC Accelerator pilot –SME Instrument - Green Deal Call for proposal H2020-EIC-SMEInst-2018-2020 See other projects for this call Sub call H2020-EIC-SMEInst-2018-2020-4 Funding Scheme SME-2 - SME instrument phase 2 Coordinator ORF GENETICS HF Net EU contribution € 2 500 000,00 Address VIKURHVARF 7 IS-203 KOPAVOGUR Iceland See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Ísland Ísland Höfuðborgarsvæði Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 3 809 356,00
